The smoking cessation drug Chantix (varenicline) may be linked to an increased cardiovascular risk, according to a retrospective analysis of medical records of nearly 57,000 new users of the drug. The study, published in the journal American Journal of Respiratory and Critical Care Medicine, found that new users of Chantix had a statistically significant (34 percent) increased risk of being treated in an emergency department or being hospitalized for a cardiovascular event while taking the drug, compared to an observational period prior to starting Chantix. In a group of Chantix users who had not had a previous cardiovascular event, patients ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.